Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
MHRA-licensed options include semaglutide (Wegovy), liraglutide (Saxenda), orlistat, and tirzepatide (Mounjaro)
JJ, and lets book an appointment
Novo Nordisk and Eli Lilly continue to dominate., Although Pfizer discontinued its in-house oral GLP-1 candidate danuglipron in April 2025 following a liver-injury signal, it has doubled back into obesity and GLP-1 with its multi-billion-dollar acquisition of Metsera
Graphical Abstract Highlights GLP-1RAs promoted weight loss in post-bariatric surgery patients faced with weight regain or insufficient weight loss
Our Range Blockbuster Deals Stacks For You
US$ 25.10
US$ 25.98
US$ 24.57
US$ 29.85
